Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
Rosalba Torrisi(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Vera Basilico(Humanitas Mater Domini), Giovanna Masci(Humanitas University), Carlo Carnaghi(Fondazione Humanitas per la Ricerca), Francesco Gentile(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Raffaella Palumbo(Fondazione Salvatore Maugeri), Bethania Fernandes(Humanitas University), Giuseppe Saltalamacchia, Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Rita De Sanctis(Humanitas University), Valentina Vaira(University of Milan)
Cited by 8
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532